Medolife Rx Presents Its Venom-To-Drug Development Projects at an International Conference Held in the Dominican Republic
Retrieved on:
Tuesday, January 11, 2022
Energy, Ministry, COVID 19, Technology, Dominican Republic, List of environmental ministries, Human, Forward-looking statement, Biodiversity, Scorpion, R, Ministry of National Planning and Economic Development, OTCQB, COVID-19, Federal republic, GLOBE, Female, Genetic resources, FINRA, Social Analysis (journal), Natural Resources, Ambassador, Multilateralism, Department, DNA, U.S. Securities and Exchange Commission, Time, Beauty, Goal, Private Securities Litigation Reform Act, Company, Plasma protein binding, Cancer, Protected area, Peptide, MOE, Security (finance), PIND, Terminology, COVID, Fine chemical, Risk management, Environment, Quanta, Rhopalurus junceus
Medolife is also committed to hire and train more female employees in 2022.
Key Points:
- Medolife is also committed to hire and train more female employees in 2022.
- CEO of Medolife Dr. Arthur Mikaelian led discussions on the Companys projects with various representatives of the international committee during the conference.
- Some members of the conference expressed interest in presenting our project to their respective countries, said Dr. Mikaelian.
- Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products.